TPO and autoimmune thrombocytopenic purpura: Immune thrombocytopenia, for instance, can be treated with a thrombopoietin (TPO) analogue, addressing both the increased demand on platelet production posed by the immune thrombocytopenia (ITP) and the platelet production deficit directly related to dysmegakaryopoiesis as a feature of CMML.